UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO of United Therapeutics Corp) exercised 9,500 stock options and sold 10,400 shares of UTHR common stock via a trust under a 10b5-1 plan on July 29, 2026.

On July 29, 2026, United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, via a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring 9,500 shares of common stock, and on the same day sold an aggregate 10,400 shares of common stock in multiple open market transactions at weighted average prices between approximately $518.25 and $525.46 per share, all pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The option exercises added 9,500 shares to indirect trust holdings, while the sales modestly reduced the trust’s indirect ownership from 333,943 shares to 324,443 shares reported for that trust, with total indirect and direct holdings across various trusts and accounts remaining substantial in dollar terms. The underlying option award, originally granted on March 15, 2023 and expiring March 15, 2027, was partially exercised, and the 10b5-1 plan contemplates potential exercise of up to 1,734,410 options through the earlier of December 31, 2026 or option expiration, indicating a structured, programmatic liquidity and diversification strategy rather than an ad hoc disposition.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000109

Alert Tier

6